Physician profile
John West
NPI 1235199274
$600.71
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $351 · 2021: $103.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $96.49 | 2020 | |
| Amgen INC. | $73.94 | 2020-2021 | |
| Tersera Therapeutics LLC | $71.46 | 2019-2020 | |
| Celgene Corporation | $63.05 | 2019 | |
| Eisai INC. | $55.59 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $45.24 | 2020 | |
| Daiichi Sankyo INC. | $36.43 | 2020-2021 | |
| Heron Therapeutics, INC. | $35.01 | 2020-2021 | |
| Genentech USA, INC. | $33.13 | 2019-2020 | |
| Immunomedics, INC. | $21.34 | 2020 | |
| Seagen INC. | $21.30 | 2021 | |
| Olympus America INC. | $18.50 | 2020 | |
| Karyopharm Therapeutics INC. | $14.66 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $14.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.